The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis

Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Zachary J., Goutagny, Nadege, Perera, Pin-Yu, Kato, Hiroki, Kumar, Himanshu, Kawai, Taro, Akira, Shizuo, Savan, Ram, van Echo, David, Fitzgerald, Katherine A., Young, Howard A., Ching, Lai-Ming, Vogel, Stefanie N.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2007
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118649/
https://www.ncbi.nlm.nih.gov/pubmed/17562815
http://dx.doi.org/10.1084/jem.20061845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118649/
https://www.ncbi.nlm.nih.gov/pubmed/17562815
http://dx.doi.org/10.1084/jem.20061845

Ejemplares similares